These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33010413)

  • 1. Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis.
    Shah ED; Salwen-Deremer JK; Gibson PR; Muir JG; Eswaran S; Chey WD
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):136-144.e31. PubMed ID: 33010413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.
    Shah ED; Saini SD; Chey WD
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2687-2695.e11. PubMed ID: 30831219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis.
    Shah ED; Salwen-Deremer JK; Gibson PR; Muir JG; Eswaran S; Chey WD
    MDM Policy Pract; 2021; 6(1):2381468320978417. PubMed ID: 33521290
    [No Abstract]   [Full Text] [Related]  

  • 4. Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis.
    Shah ED; Chang L; Salwen-Deremer JK; Gibson PR; Keefer L; Muir JG; Eswaran S; Chey WD
    Am J Gastroenterol; 2021 Apr; 116(4):748-757. PubMed ID: 33982945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.
    Shah ED; Chang L; Lembo A; Staller K; Curley MA; Chey WD
    Dig Dis Sci; 2021 Dec; 66(12):4140-4148. PubMed ID: 33433804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.
    Wechsler EV; Shah ED
    Drugs; 2021 Nov; 81(17):1953-1968. PubMed ID: 34727333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.
    Lacy BE; Gagnon-Sanschagrin P; Heimanson Z; Bungay R; Bellefleur R; Guérin A; Bumpass B; Borroto D; Joseph G; Dashputre AA
    Adv Ther; 2024 Jun; 41(6):2253-2266. PubMed ID: 38619720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of internet-delivered cognitive-behavioural therapy for adolescents with irritable bowel syndrome.
    Sampaio F; Bonnert M; Olén O; Hedman E; Lalouni M; Lenhard F; Ljótsson B; Ssegonja R; Serlachius E; Feldman I
    BMJ Open; 2019 Jan; 9(1):e023881. PubMed ID: 30679293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.
    Almario CV; Noah BD; Jusufagic A; Lew D; Spiegel BMR
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1434-1441.e21. PubMed ID: 29596984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
    Olden KW; Chey WD; Shringarpure R; Paul Nicandro J; Chuang E; Earnest DL
    Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
    Brenner DM; Sayuk GS
    Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
    Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
    Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome.
    Weerts ZZRM; Essers BAB; Jonkers DMAE; Willems JIA; Janssen DJPA; Witteman BJM; Clemens CHM; Westendorp A; Masclee AAM; Keszthelyi D
    United European Gastroenterol J; 2021 Nov; 9(9):997-1006. PubMed ID: 34468079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome.
    Munjal A; Dedania B; Cash BD
    Expert Opin Pharmacother; 2020 Jan; 21(1):63-71. PubMed ID: 31738621
    [No Abstract]   [Full Text] [Related]  

  • 19. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Sultan S; Chang L; Heidelbaugh JJ; Smalley W; Verne GN
    Gastroenterology; 2022 Jul; 163(1):137-151. PubMed ID: 35738725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.